公开(公告)号：US20040018200A1

公开(公告)日：2004-01-29

申请号：US10461863

申请日：2003-06-13

申请人： MedImmune, Inc.

发明人： Cynthia N. Oliver ,  Christian B. Allan ,  Stephen T. Chang

IPC分类号： A61K039/42

CPC分类号： C07K16/1027 ,  A61K9/0019 ,  A61K9/0043 ,  A61K39/39591 ,  A61K39/42 ,  A61K47/183 ,  A61K2039/505 ,  C07K2317/56 ,  C07K2317/565 ,  A61K2300/00

摘要： The present invention provides liquid formulations of antibodies or fragments thereof that immunospecifically bind to a respiratory syncytial virus (RSV) antigen, which formulations exhibit stability, low to undetectable levels of aggregation, and very little to no loss of the biological activities of the antibodies or antibody fragments, even during long periods of storage. In particular, the present invention provides liquid formulations of antibodies or fragments thereof that immunospecifically bind to a RSV antigen, which formulations are substantially free of surfactant, inorganic salts, and/or other common excipients. Furthermore, the invention provides methods of preventing, treating or ameliorating one or more symptoms associated with RSV infection utilizing the liquid formulations of the present invention.

摘要翻译： 本发明提供免疫特异性结合呼吸道合胞病毒（RSV）抗原的抗体或其片段的液体制剂，该制剂表现出稳定性，低至不可检测的聚集水平，以及抗体的生物活性几乎至不损失，或 抗体片段，即使在长时间的储存期间。 特别地，本发明提供免疫特异性结合RSV抗原的抗体或其片段的液体制剂，该制剂基本上不含表面活性剂，无机盐和/或其它常见的赋形剂。 此外，本发明提供使用本发明的液体制剂预防，治疗或改善与RSV感染相关的一种或多种症状的方法。

公开(公告)号：US20020177126A1

公开(公告)日：2002-11-28

申请号：US09996288

申请日：2001-11-28

申请人： MedImmune, Inc.

发明人： James F. Young ,  Scott Koenig ,  Leslie S. Johnson

IPC分类号： C12P021/08 ,  C07K016/00 ,  C12N005/16 ,  C12N005/06 ,  A61K039/42 ,  C07H021/04 ,  C12Q001/70

CPC分类号： C07K16/1027 ,  A61K2039/505 ,  C07K2317/24 ,  C07K2317/56 ,  C07K2317/565

摘要： The present invention encompasses novel antibodies and fragments thereof which immunospecifically bind to one or more RSV antigens and compositions comprising said antibodies and antibody fragments. The present invention encompasses methods preventing respiratory syncytial virus (RSV) infection in a human, comprising administering to said human a prophylactically effective amount of one or more antibodies or fragments thereof that immunospecifically bind to one or more RSV antigens, wherein a certain serum titer of said antibodies or antibody fragments is achieved in said human subject. The present invention also encompasses methods for treating or ameliorating symptoms associated with a RSV infection in a human, comprising administering to said human a therapeutically effective amount of one or more antibodies or fragments thereof that immunospecifically bind to one or more RSV antigens, wherein a certain serum titer of said antibodies or antibody fragments is achieved in said human subject. The present invention further encompasses compositions comprising antibodies or fragments thereof that immunospecifically bind to a RSV antigen, and methods using said compositions for detection or diagnosis a RSV infection.

摘要翻译： 本发明包括免疫特异性结合一种或多种RSV抗原的新型抗体及其片段，以及包含所述抗体和抗体片段的组合物。 本发明包括预防人类呼吸道合胞病毒（RSV）感染的方法，包括向所述人施用预防有效量的一种或多种免疫特异性结合一种或多种RSV抗原的抗体或其片段，其中一定的血清滴度为 所述抗体或抗体片段在所述人受试者中实现。 本发明还包括用于治疗或改善与人类RSV感染有关的症状的方法，包括向所述人施用治疗有效量的一种或多种免疫特异性结合一种或多种RSV抗原的抗体或其片段，其中一定 所述抗体或抗体片段的血清滴度在所述人受试者中实现。 本发明还包括包含免疫特异性结合RSV抗原的抗体或其片段的组合物，以及使用所述组合物检测或诊断RSV感染的方法。

公开(公告)号：US5824307A

公开(公告)日：1998-10-20

申请号：US290592

申请日：1994-08-15

申请人： Leslie Sid Johnson

发明人： Leslie Sid Johnson

IPC分类号： C12N15/09 ,  A61K38/00 ,  A61K39/395 ,  A61K39/42 ,  A61P31/12 ,  C07K14/08 ,  C07K14/46 ,  C07K16/08 ,  C07K16/10 ,  C12P21/08

CPC分类号： C07K16/1027 ,  A61K2039/505 ,  A61K38/00 ,  C07K2317/24 ,  C07K2317/30 ,  C07K2317/76 ,  C07K2317/92 ,  C07K2319/00

摘要： This invention relates to a human antibody which contains the one CDR from each variable heavy and variable light chain of at least one murine monoclonal antibody, against respiratory syncytial virus which is MAb1129 and the use thereof for the prevention and/or treatment of RSV infection.

公开(公告)号：US5583038A

公开(公告)日：1996-12-10

申请号：US977630

申请日：1992-11-17

申请人： Charles K. Stover

发明人： Charles K. Stover

IPC分类号： C12N15/09 ,  A61K39/00 ,  A61K39/04 ,  A61K39/395 ,  A61P31/04 ,  C07K14/20 ,  C07K14/315 ,  C07K14/35 ,  C12N1/21 ,  C12N15/62 ,  C12N15/74 ,  C12P21/02 ,  C12R1/32

CPC分类号： C07K14/3156 ,  C07K14/20 ,  C07K14/35 ,  C12N15/625 ,  C12N15/74 ,  A61K39/00 ,  C07K2319/035 ,  C07K2319/40 ,  C07K2319/915

摘要： An expression vector for expressing a protein or polypeptide in a bacterium, which comprises a first DNA sequence encoding at least a secretion signal of a lipoprotein, and a second DNA sequence encoding a protein or fragment thereof, or polypeptide or peptide heterologous to the bacterium which expresses the protein or fragment thereof, or polypeptide or peptide. The bacterium expresses a fusion protein a lipoprotein or lipoprotein segment and the protein or fragment thereof, or polypeptide or peptide heterologous to the bacterium which expresses the protein or fragment thereof, or polypeptide or peptide. Such expression vectors increase the immunogenicity of the protein or fragment thereof, or polypeptide or peptide by enabling the protein or fragment thereof, or polypeptide or peptide to be expressed on the surface of the bacterium. Bacteria which may be transformed with the expression vector include mycobacteria such as BCG. The expression vectors of the present invention may be employed in the formation of live bacterial vaccines against Lyme disease wherein the bacteria express a surface protein of Borrelia burgdorferi, the causative agent of Lyme disease.

摘要翻译： 用于在细菌中表达蛋白质或多肽的表达载体，其包含编码脂蛋白的至少一种分泌信号的第一DNA序列和编码其蛋白质或其片段的第二DNA序列，或与该细菌异源的多肽或肽 表达蛋白质或其片段，或多肽或肽。 该细菌表达融合蛋白质的脂蛋白或脂蛋白片段及其与表达其蛋白质或片段，或多肽或肽的细菌异源的蛋白质或片段，或多肽或肽。 这种表达载体通过使蛋白质或其片段或多肽或肽在细菌表面上表达而增加蛋白质或其片段或多肽或肽的免疫原性。 可用表达载体转化的细菌包括分枝杆菌如BCG。 本发明的表达载体可以用于形成针对莱姆病的活细菌疫苗，其中细菌表达布氏疏螺旋体的表面蛋白，其是莱姆病的致病因子。

公开(公告)号：US20080089931A1

公开(公告)日：2008-04-17

申请号：US11953653

申请日：2007-12-10

申请人： Michael Kinch

发明人： Michael Kinch

IPC分类号： A61K9/50 ,  A61K31/70 ,  A61P35/00 ,  A61K39/395

CPC分类号： A61K38/1709 ,  A61K9/127 ,  A61K48/00 ,  A61K2039/505 ,  C07K16/2866 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/622 ,  C12N9/12 ,  C12N9/16 ,  C12Y301/03048

摘要： The present invention relates to methods and compositions designed for treatment, management, or prevention of a hyperproliferative cell disease, particular cancer. The methods of the invention comprise the administration of an effective amount of a composition that targets cells expressing low molecular weight protein tyrosine kinase (“LMW-PTP”) in particular using moieties that bind an Eph family receptor tyrosine kinase, such as EphA2 or EphA4, and inhibits or reduces LMW-PTP expression and/or activity. In one embodiment, the method of the invention comprises administering to a subject a composition comprising an EphA2 or EphA4 targeting moiety attached to a delivery vehicle, and one or more agents that inhibit LMW-PTP expression and/or activity operatively associated with the delivery vehicle. In another embodiment, the method of the invention comprises administering to a subject a composition comprising a nucleic acid comprising a nucleotide sequence encoding an EphA2 or EphA4 targeting moiety and an agent that inhibits or reduces LMW-PTP expression and/or activity. In yet another embodiment, the method of the invention comprises administering to a subject a composition comprising an EphA2 or EphA4 targeting moiety and a nucleic acid comprising a nucleotide sequence encoding an agent that inhibits or reduces LMW-PTP expression and/or activity, where the nucleic acid is operatively associated with the delivery vehicle. Pharmaceutical compositions are also provided by the present invention.

摘要翻译： 本发明涉及用于治疗，治疗或预防过度增殖性细胞疾病，特定癌症的方法和组合物。 本发明的方法包括施用有效量的靶向表达低分子量蛋白酪氨酸激酶（“LMW-PTP”）的细胞的组合物，特别是使用结合Eph家族受体酪氨酸激酶（例如EphA2或EphA4）的部分 ，并且抑制或降低LMW-PTP表达和/或活性。 在一个实施方案中，本发明的方法包括向受试者施用包含与递送载体​​连接的EphA2或EphA4靶向部分的组合物，以及一种或多种抑制LMW-PTP表达和/或与递送载体​​可操作地相关的活性的试剂 。 在另一个实施方案中，本发明的方法包括向受试者施用包含核酸的组合物，所述核酸包含编码EphA2或EphA4靶向部分的核苷酸序列和抑制或降低LMW-PTP表达和/或活性的试剂。 在另一个实施方案中，本发明的方法包括向受试者施用包含EphA2或EphA4靶向部分的组合物和包含编码抑制或降低LMW-PTP表达和/或活性的试剂的核苷酸序列的核酸，其中 核酸与递送载体​​可操作地相关联。 药物组合物也由本发明提供。

公开(公告)号：US07323172B2

公开(公告)日：2008-01-29

申请号：US10962285

申请日：2004-10-08

申请人： James F. Young ,  Scott Koenig ,  Leslie S. Johnson ,  William D. Huse ,  Jeffrey D. Watkins ,  Herren Wu

发明人： James F. Young ,  Scott Koenig ,  Leslie S. Johnson ,  William D. Huse ,  Jeffrey D. Watkins ,  Herren Wu

IPC分类号： A61K39/42 ,  A61K39/155

CPC分类号： C07K16/1027 ,  A61K2039/505 ,  C07K2317/24 ,  C07K2317/56 ,  C07K2317/565

摘要： The present invention encompasses novel antibodies and fragments thereof which immunospecifically bind to one or more RSV antigens and compositions comprising said antibodies and antibody fragments. The present invention encompasses methods preventing respiratory syncytial virus (RSV) infection in a human, comprising administering to said human a prophylactically effective amount of one or more antibodies or fragments thereof that immunospecifically bind to one or more RSV antigens, wherein a certain serum titer of said antibodies or antibody fragments is achieved in said human subject. The present invention also encompasses methods for treating or ameliorating symptoms associated with a RSV infection in a human, comprising administering to said human a therapeutically effective amount of one or more antibodies or fragments thereof that immunospecifically bind to one or more RSV antigens, wherein a certain serum titer of said antibodies or antibody fragments is achieved in said human subject. The present invention further encompasses compositions comprising antibodies or fragments thereof that immunospecifically bind to a RSV antigen, and methods using said compositions for detection or diagnosis a RSV infection.

摘要翻译： 本发明包括免疫特异性结合一种或多种RSV抗原的新型抗体及其片段，以及包含所述抗体和抗体片段的组合物。 本发明包括预防人类呼吸道合胞病毒（RSV）感染的方法，包括向所述人施用预防有效量的一种或多种免疫特异性结合一种或多种RSV抗原的抗体或其片段，其中一定的血清滴度为 所述抗体或抗体片段在所述人受试者中实现。 本发明还包括用于治疗或改善与人类RSV感染有关的症状的方法，包括向所述人施用治疗有效量的一种或多种免疫特异性结合一种或多种RSV抗原的抗体或其片段，其中一定 所述抗体或抗体片段的血清滴度在所述人受试者中实现。 本发明还包括包含免疫特异性结合RSV抗原的抗体或其片段的组合物，以及使用所述组合物检测或诊断RSV感染的方法。

公开(公告)号：US07309490B2

公开(公告)日：2007-12-18

申请号：US11198323

申请日：2005-08-08

申请人： Scott Koenig

发明人： Scott Koenig

IPC分类号： A61K39/00 ,  A61K39/395

CPC分类号： C07K16/1027 ,  A61K39/00 ,  A61K39/395 ,  A61K39/40 ,  A61K39/42 ,  A61K2039/505 ,  A61K2039/545 ,  Y02A50/464 ,  Y02A50/466 ,  Y02A50/474

摘要： Disclosed are methods for vaccine priming, using co-treatment, at a temporally similar or at a previous time, with a priming antibody capable of priming, or enhancing, or potentiating the effects of a vaccine, or vaccine composition. Also disclosed are methods of using this process to prevent or treat disease.

摘要翻译： 公开了疫苗引发的方法，其使用能够在时间上相似或以前的时间使用能够引发或增强或增强疫苗或疫苗组合物的作用的引发抗体进行共同治疗。 还公开了使用该方法预防或治疗疾病的方法。

公开(公告)号：US07208162B2

公开(公告)日：2007-04-24

申请号：US09848377

申请日：2001-05-03

申请人： Gregory Prince ,  Leslie S. Johnson

发明人： Gregory Prince ,  Leslie S. Johnson

IPC分类号： A61K39/155

CPC分类号： C07K16/1027 ,  A61K39/42 ,  A61K2039/505 ,  A61K2300/00

摘要： Therapeutically effective anti-viral compositions, useful especially against respiratory diseases caused or mediated by respiratory syncytial virus (RSV) are disclosed, wherein said compositions comprise at least one anti-RSV antibody, including high affinity antibodies, and an additional anti-inflammatory agent, especially corticosteroids, as well as anti-inflammatory antibodies, especially anti-interleukin-6. Also disclosed are methods of using such compositions to treat and/or prevent respiratory diseases. Such compositions may optionally contain other non-antibody anti-viral agents.

公开(公告)号：US07132100B2

公开(公告)日：2006-11-07

申请号：US10461904

申请日：2003-06-13

申请人： Cynthia N. Oliver ,  Erica Shane ,  Benjamin S. Isaacs ,  Christian B. Allan ,  Stephen T. Chang

发明人： Cynthia N. Oliver ,  Erica Shane ,  Benjamin S. Isaacs ,  Christian B. Allan ,  Stephen T. Chang

IPC分类号： A61K39/395 ,  A61K39/40 ,  A61K39/42 ,  C07K16/00

CPC分类号： C07K16/1027 ,  A61K9/0019 ,  A61K9/0043 ,  A61K39/39591 ,  A61K39/42 ,  A61K47/183 ,  A61K47/22 ,  A61K47/26 ,  A61K2039/505 ,  A61K2039/54 ,  C07K16/00 ,  C07K2317/24 ,  C07K2317/565 ,  C07K2317/94

摘要： The present invention provides liquid formulations of SYNAGIS® or an antigen-binding fragment thereof that immunospecifically bind to a respiratory syncytial virus (RSV) antigen, which formulations exhibit stability, low to undetectable levels of aggregation, and very little to no loss of the biological activities of SYNAGIS® or an antigen-binding fragment thereof, even during long periods of storage. In particular, the present invention provides liquid formulations of SYNAGIS® or an antigen-binding fragment thereof which immunospecifically binds to a RSV antigen, which formulations are substantially free of surfactant, inorganic salts, and/or other common excipients. Furthermore, the invention provides method of preventing, treating or ameliorating symptoms associated with RSV infection utilizing liquid formulations of the present invention.

摘要翻译： 本发明提供了免疫特异性结合呼吸道合胞病毒（RSV）抗原的SYNAGIS或其抗原结合片段的液体制剂，该制剂表现出稳定性，低至不可检测的聚集水平，以及很少甚至没有损失 SYNAGIS或其抗原结合片段的生物活性，甚至在长时间的储存期间。 特别地，本发明提供了SYNAGIS或其抗原结合片段的液体制剂，其免疫特异性结合RSV抗原，该制剂基本上不含表面活性剂，无机盐和/或其它常见赋形剂。 此外，本发明提供使用本发明的液体制剂预防，治疗或改善与RSV感染相关的症状的方法。

公开(公告)号：US20060228350A1

公开(公告)日：2006-10-12

申请号：US11377148

申请日：2006-03-17

申请人： Herren Wu ,  William Dall-Acqua ,  Melissa Damschroder

发明人： Herren Wu ,  William Dall-Acqua ,  Melissa Damschroder

IPC分类号： A61K39/395 ,  C07H21/04 ,  C12P21/06 ,  C07K16/44 ,  C12N5/06

CPC分类号： C07K16/005 ,  C07H21/04 ,  C07K16/2863 ,  C07K16/40 ,  C07K16/464 ,  C07K2317/55 ,  C07K2317/92 ,  C12N15/1027

摘要： The present invention relates to methods of reengineering or reshaping antibodies to reduce the immunogenicity of the antibodies, while maintaining the immunospecificity of the antibodies for an antigen. In particular, the present invention provides methods of producing antibodies immunospecific for an antigen by synthesizing a combinatorial library comprising complementarity determining regions (CDRs) from a donor antibody fused in frame to framework regions from a sub-bank of framework regions. The invention also provides method of producing improved humanized antibodies. The present invention also provides antibodies produced by the methods of the invention.

摘要翻译： 本发明涉及重新设计或重塑抗体以降低抗体免疫原性的方法，同时保持针对抗原的抗体的免疫特异性。 特别地，本发明提供了通过合成包含来自框架区域的子库的框架区域融合的供体抗体的互补决定区（CDR）的组合文库的组合文库来产生针对抗原免疫特异性的抗体的方法。 本发明还提供了生产改良的人源化抗体的方法。 本发明还提供通过本发明的方法制备的抗体。